Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Inventiva S.A.NASDAQ: IVA

Net Receivables · Q4 FY2025 · quarter ended Dec 2025

Net receivables falls 25.0% from a year ago

Net receivables stood at €9.12M at the end of Q4 FY2025, down 25.0% from a year earlier. Over 3 fiscal years it compounded at +219.7% a year.

Context

  • Net receivables amounted to 3.7% of total assets at the end of Q4 FY2025, down 6.6 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -25.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
€9.12M— QoQ
Last fiscal yearDec 2025
€9.12M-25.0% YoY
Year agoDec 2024
€12.16M-25.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.0%——
1 year-25.0%——
3-year CAGR+219.7%——
5-year CAGR——
10-year CAGR——

Net Receivables history

EUR · from the balance sheet

Latest · FY2025
9.12M EUR
Year-over-year change
-25.0%
4-year CAGR
-5.8%

Net Receivables vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -25.0% is the 5th highest of 7, against a peer median of -9.7%.
  • Net receivables amounts to 3.7% of total assets for IVA, versus a peer median of 0.5%.
IVA Competitors
Net Receivables for IVA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IVVDInvivyd, Inc.Mar 2026$12.21M USD+39.5%+238.3%5.1%
TNYATenaya Therapeutics, Inc.Mar 2026$10.63M USD——7.9%
IVAInventiva S.A.Dec 2025€9.12M EUR-25.0%+219.7%3.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$7.83M USD-80.7%-48.0%2.5%
CRBUCaribou Biosciences, Inc.Mar 2026$2.36M USD-13.8%-13.9%1.6%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$665.42K USD+179.0%—0.5%
RNACCartesian Therapeutics, Inc.Mar 2026$261K USD-85.2%-51.6%0.1%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$84K USD-5.6%-0.3%0.1%
AVTXAvalo Therapeutics, Inc.Mar 2026$0 USD——0.0%
NAUTNautilus Biotechnology, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding IVA) —-9.7%-13.9%0.5%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents86.55M86.74M26.92M96.56M99.27M
Short-term Investments01.05M70K00
Net Receivables11.59M279K15.71M12.16M9.12M
Inventory392K373K417K00
Other Current Assets9.59M9.35M69K349K131.5M
Total Current Assets115.58M106.38M48.19M111.51M243.84M
Property, Plant & Equipment (Net)3.2M7.39M9.13M5.01M2.98M
Goodwill00000
Intangible Assets770K568K541K48K181.92K
Long-term Investments1.75M700K1.43M1.14M526.78K
Tax Assets699K0225K217K190.92K
Other Non-current Assets(2K)968K10.05M1.05M1.16M
Total Non-current Assets6.41M9.62M21.37M7.46M5.04M
Total Assets121.99M116M69.56M118.97M248.88M
Account Payables14.6M19.36M37.68M32.86M26.01M
Short-term Debt1.24M4.57M3.01M3.35M30.27M
Tax Payables1.06M2.14M3.57M3.92M0
Deferred Revenue06K6K00
Other Current Liabilities5.74M2.28M5.63M73.4M8.29M
Total Current Liabilities22.85M30.7M50.16M120.73M77.35M
Long-term Debt8.75M25.43M27.91M46.33M24.77M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)055K0107K125.95K
Other Non-current Liabilities1.43M11.11M19.25M56.31M172.9M
Total Non-current Liabilities10.27M39.83M51.43M104.88M200.57M
Total Liabilities33.12M70.53M101.59M225.61M277.91M
Common Stock409K421K521K957K1.93M
Retained Earnings(49.64M)(54.27M)(110.43M)(184.21M)(354.14M)
Accumulated OCI(26.98M)(74.56M)(123.99M)(172.55M)(204.55M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity88.87M45.48M(32.03M)(106.65M)(29.04M)
Total Debt10.12M34.51M37.49M54.33M59.4M
Net Debt(76.43M)(52.22M)10.57M(42.23M)(39.87M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.